WO2025219924 - CELL LINES OVEREXPRESSING VESICULAR STOMATITIS VIRUS G
National phase entry is expected:
Publication Number
WO/2025/219924
Publication Date
23.10.2025
International Application No.
PCT/IB2025/054035
International Filing Date
17.04.2025
Title **
[English]
CELL LINES OVEREXPRESSING VESICULAR STOMATITIS VIRUS G
[French]
LIGNÉES CELLULAIRES SUREXPRIMANT LE VIRUS DE LA STOMATITE VÉSICULAIRE G
Applicants **
CSL BEHRING LLC
Inventors
KLIMPEL, Maximillian
LAUX, Holger
Priority Data
63/636,201
19.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3325 | |
| EPO | Filing, Examination, Granting | 27917 | |
| Japan | Filing, Examination, Granting | 3083 | |
| South Korea | Filing, Examination, Granting | 3987 | |
| USA | Filing, Examination, Granting | 13310 |
Total:
51,622
Contact Us
Abstract[English]
The present disclosure generally relates to the manufacturing of gene therapy products, and specifically to methods of producing an enveloped virus from a stable producer cell clone or a stable producer cell pool overexpressing vesicular stomatitis virus G (VSV-G) in suspension cell culture.[French]
La présente invention concerne de manière générale la fabrication de produits de thérapie génique, et plus particulièrement des procédés de production d'un virus enveloppé à partir d'un clone de cellule productrice stable ou d'un groupe de cellules productrices stables surexprimant le virus de la stomatite vésiculaire G (VSV-G) dans une culture cellulaire en suspension.